Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs (MERAK)
This study has been completed.
Study NCT00828971   Information provided by Bayer

First Received on January 23, 2009.   Last Updated on January 9, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Infectious Diseases
Additional conditions recognized in this trial
Communicable Diseases
Infection
Interventions listed in this trial
Avelox (Moxifloxacin, BAY12-8039)
Amoxicilline/clavulanic
Additional drug interventions recognized in this trial
Amoxicillin
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acid
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services